Evidence map›Paper›PMID 35589418›Full record

ReviewJournal of the National Medical Association2022

Etiopathogenesis of kidney disease in minority populations and an updated special focus on treatment in diabetes and hypertension.

Ebele M Umeukeje, Jasmine T Washington, Susanne B Nicholas

Open access · greenAbstract readReview
In one paragraph

Review in Journal of the National Medical Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Outcomes After Traumatic Brain Injury Surgery: Investigating Racial Disparities.Journal of racial and ethnic health disparities · 2026
    Article
  3. Article
  4. Article
  5. Surgical Outcomes and Sociodemographic Disparities Across All Races: An ACS-NSQIP and NHIS Multi-Institutional Analysis of Over 7.5 Million Patients.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ebele M UmeukejeDivision of Nephrology, Vanderbilt University Medical Center, Vanderbilt Center for Kidney Disease, United States.
Jasmine T WashingtonHattiesburg Clinic, Hattiesburg, MS, United States.
Susanne B NicholasDavid Geffen School of Medicine at University of California, 7-155 Factor Bldg. 10833 LeConte Blvd, Los Angeles, CA 90095, United States. Electronic address: sunicholas@mednet.ucla.edu.
Hattiesburg Clinic · USVanderbilt University Medical Center · US

Funding

Prediction of Chronic Kidney Disease by Simulation Modeling to Improve the Health of Minority PopulationsR01MD014712 · NIMHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUI, ALEX, NICHOLAS, SUSANNE B · 2020 to 2023
$1.5M
Patient-centered Approach To Improving Dialysis Adherence in African AmericansK23DK114566 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI UMEUKEJE, EBELE M · 2018 to 2022
$929k
MOVE: MOtiVational Strategies To Empower African Americans To Improve Dialysis AdherenceR03DK129626 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI UMEUKEJE, EBELE M · 2021 to 2022
$260k
NIDDK NIH HHS K23 DK114566NIDDK NIH HHS R03 DK129626NIMHD NIH HHS R01 MD014712
6 · The paper itself

Abstract

Diabetes and hypertension are the most common causes of chronic kidney disease (CKD) in the general population as well as in the Black and African American population, who also suffer from high rates of CKD and CKD progression compared to the White population. Progression of CKD can lead to kidney failure, and patients with progressive kidney disease have a high risk of premature mortality, particularly from cardiovascular disease. Screening for early detection of CKD is important as it facilitates the initiation of medications that have been shown to delay the progression of diabetes-related as well as non-diabetes-related CKD, and reduce rates of death from both kidney and cardiovascular disease. The potential adverse effects from use of some of the newer reno- and cardio-protective glucose-lowering medications, such as the sodium glucose cotransporter-2 inhibitors, may be effectively avoided with detailed patient education and monitoring by the healthcare provider. It is important to note that lifestyle modification including regular exercise, diet, and smoking cessation are first-line in the management of diabetes and hypertension. When CKD occurs, co-management by providers using a comprehensive strategy may avert early complications and facilitate appropriate early referral for nephrology specialty care.

Indexed as

Cardiovascular DiseasesDiabetes MellitusHypertensionRenal Insufficiency, ChronicHumansMinority GroupsAngiotensin converting enzyme inhibitorsAngiotensin receptor blockersChronic kidney diseaseDiabetesHypertensionSodium glucose co-transporter-2 inhibitors

Identifiers

PMID35589418
PMCPMC9400490
OpenAlexW4280606508

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.